Founded in 2025, Orchid Therapeutics Ltd is dedicated to the field of Cell and Gene Therapy (CGT), focusing on the research and development of innovative drugs with transformative therapeutic efficacy. The company’s product pipeline covers a wide range of ex vivo and in vivo CAR cell therapy candidates against multiple targets. Our indications span hematological malignancies, solid tumors and autoimmune diseases. We have independently built a full-chain core technology platform encompassing antibody screening, CAR-T design and validation, plasmid vector process development, gene editing, non-viral delivery systems, targeted lentiviral delivery systems, as well...